|
10th Anniversary Conference Of The British HIV Association [BHIVA]15 – 17 April 2004, City Hall, Cardiff, UK |
[AUTHOR(S):] C McDonald1, N Mackie2, C Smyth1, N Tamm2, R Weston2, G Scullard2, M Fisher1
1Brighton and Sussex University Hospitals, 2St Mary's Hospital, London, UK
BHIVA Conf 2004 Apr 15-17;10:O2
INTRODUCTION: Atazanavir (ATV) is a new protease inhibitor (PI) with potential advantages of once-daily administration, low pill burden and less reported hyperlipidaemia.
METHODS: Patients attending two HIV clinics and receiving ATV were included. Demographic details, reasons for using ATV, surrogate marker responses and toxicities (pre- and post-ATV) were collected.
RESULTS: 76 patients received ATV for a median of 15 weeks (range 1–47). The median time on antiretroviral therapy was 64 months and the duration of prior PI therapy 23 months. Reasons for starting ATV included pill burden (20), once-daily therapy (21), adherence issues (9), hyperlipidaemia (20), gastrointestinal disturbance (11), lipodystrophy (6) and virological failure (13). Two patients died (unrelated to ATV); six stopped ATV because of patient choice (3), hypersensitivity (1), jaundice (1) and myositis (1). One was lost to follow-up. 28 switched to ATV with a viral load of <50 HIV-1 RNA copies/ml, and 27 remain with <50copies/ml; 44 started with detectable viraemia, 22 are now undetectable and the remaining 16 on therapy have experienced significant viral load reductions. Hyperbilirubinaemia occurred in 64%, resolving in 61%; three experienced clinical jaundice. Hyperlipidaemia improved in 61%, with 38% able to stop lipid-lowering agents. Improvements in gastrointestinal symptoms occurred in 54%.
CONCLUSION: ATV is well tolerated, efficacious and enables resolution of PI-related toxicity in many recipients.
PRESENTING AUTHOR: C McDonald
040415
O2
Copyright © 2004 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD